Pharma IQ Members

Market Access

Find out everything you need to know about the latest pricing, reimbursement and market access strategies that will drive your business development.

Posted: 27/09/2012
The Launch of Once-Daily Pill Gives New Hope for Epilepsy Patients

Japanese pharmaceutical giant Eisai has launched a new epilepsy drug in Europe following approval by the European Commission.

Discovered and developed in the United Kingdom, Fycompa® (perampanel) is an important new addition to the treatment of epilepsy in Europe as it has efficacy in difficult-to-treat patients with uncontrolled partial o Full Video »
Contributor: Andrea Charles
Posted: 19/12/2011
Diabetes is a global threat. Researchers estimate that 26.6 million people in the Middle East and North Africa currently have diabetes. Six countries in the region are among the top 10 globally with the highest prevalence of diabetes. In this interview Professor Peter Schwarz, Head of Department of Prevention and Care of Diabetes University Full Podcast »
Contributor: Tony Hitchcock
Posted: 22/03/2016
Tony Hitchcock
When we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear, products are becoming increasingly complex in their nature. Certainly, the complexity of the manufacturing processes used to produce them clearly reflects this; hand in hand with ever increasing product development costs and timelines. Full Column »
Contributor: Chanice Henry
Posted: 28/04/2016
Chanice Henry
While the US advances with its coverage of medical device classes within the U.S. Food and Drug Administration (FDA) Unique Device Identification regime, other countries around the globe are progressing their own track and trace strategies for medical devices. Through the collaboration of the world’s regulatory agencies it is hoped that a synchronized approach to medical device identification will be achieved on an international level, amidst their efforts to tackle counterfeiting, increase accountability and enable safety corrective measures. (2) Full Whitepaper »